# A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis

> **NCT05037760** · PHASE2 · RECRUITING · sponsor: **Takeda** · enrollment: 135 (estimated)

## Conditions studied

- Myelofibrosis

## Interventions

- **DRUG:** Elritercept
- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT05037760
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-16
- **Primary completion:** 2028-02-28
- **Final completion:** 2030-02-28
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05037760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05037760, "A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05037760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*